COHANCE - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.0
✅ Positive
Cohance Lifesciences demonstrates reasonable profitability with a 10.4% ROCE and a manageable debt-to-equity ratio of 0.03. The company’s PEG ratio of -4.06 suggests the stock is currently undervalued relative to earnings growth expectations.
⚠️ Limitation
The significant Qtr Profit Variance (-66.8%) raises concerns about recent performance, and the high P/E ratio reflects investor enthusiasm that may not be sustainable. FII holding decreased while DII holding reduced, suggesting potential waning institutional interest.
📉 Company Negative News
The reported -66.8% quarter-over-quarter profit variance indicates a substantial decline in profitability, which warrants careful examination of the underlying causes.
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is characterized by high capital expenditure, regulatory scrutiny, and intense competition, often resulting in fluctuating margins and volatile stock prices. Innovation and successful drug development are key drivers for industry success, influencing investor sentiment significantly.
🧾 Conclusion
Based on the valuation indicators and a relatively conservative estimate of future growth, an entry zone between 375 ₹ – 400 ₹ appears attractive. Holding guidance suggests a strategic approach, with investors monitoring earnings calls and potential catalysts like new product launches to refine their outlook. The company presents a moderate investment opportunity within the pharmaceutical industry.